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Abstract
Background Oncogenic drivers in solid tumors include aberrant activation of mesenchymal epithelial transition factor
(MET) and AXL.
Objective This study investigated the safety and antitumor activity of glesatinib, a multitargeted receptor tyrosine kinase
inhibitor that inhibits MET and AXL at clinically relevant doses, in combination with erlotinib or docetaxel.
Patients and Methods The phase I portion of this open-label, multicenter study included two parallel arms in which ascending
doses of oral glesatinib (starting dose 96 mg/m2) were administered with erlotinib or docetaxel (starting doses 100 mg once
daily and 50 mg/m2, respectively) using a modified 3 + 3 design. Maximum tolerated dose (MTD) was based on dose-limiting
toxicities (DLTs) during the first 21-day treatment cycle. Enrollment focused on patients with solid tumor types typically
associated with MET aberration and/or AXL overexpression. The primary objective was to determine the safety profile of
the treatment combinations. Antitumor activity and pharmacokinetics (PK) were also assessed.
Results Ten dose levels of glesatinib across three glycolate formulations (unmicronized, micronized, or micronized version
2 [V2] tablets) available during the course of the study were investigated in 14 dose-escalation cohorts (n = 126). MTDs of
unmicronized glesatinib plus erlotinib or docetaxel, and micronized glesatinib plus erlotinib were not reached. Micronized
glesatinib 96 mg/m2 plus docetaxel exceeded the MTD. Further dosing focused on glesatinib micronized V2: maximum
administered dose (MAD) was 700 mg twice daily with erlotinib 150 mg once daily or docetaxel 75 mg/m2 every 3 weeks.
DLTs, acceptable at lower glesatinib (micronized V2) dose levels, occurred in two of five and two of six patients at the
MADs of glesatinib + erlotinib and glesatinib + docetaxel, respectively. Across all cohorts, the most frequent treatmentrelated adverse events were diarrhea (glesatinib + erlotinib: 84.1%; glesatinib + docetaxel: 45.6%), fatigue (46.4%, 70.4%),
and nausea (30.4%, 35.1%). The objective response rate was 1.8% and 12.0% in all glesatinib + erlotinib and glesatinib +
docetaxel cohorts, respectively.
Conclusions The safety profile of glesatinib plus erlotinib or docetaxel was acceptable and there were no PK interactions.
MADs of glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily or docetaxel 75 mg/m2 every 3
weeks exceeded the MTD by a small margin. Modest signals of efficacy were observed with these treatment combinations
in non-genetically selected patients with advanced solid tumors.
Clinical Trials Registration ClinicalTrials.gov NCT00975767; 11 September 2009.
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Key Points
This was a phase I, open-label, dose-escalation study of
glesatinib, a multitargeted inhibitor of mutant and wildtype MET, AXL, and other receptor tyrosine kinases, in
a non-genetically selected population of patients with
advanced solid tumors.
The study demonstrated modest efficacy, an acceptable
safety profile, and no pharmacokinetic interactions for
glesatinib glycolate formulations in combination with
either erlotinib or docetaxel; exposure was suboptimal.
Further investigation of glesatinib, to be reported
separately, focused on free-base formulations, aimed
to improve drug bioavailability in patients with METactivating alterations.

1 Introduction
Binding of hepatocyte growth factor (HGF) to mesenchymal
epithelial transition factor (MET) receptor tyrosine kinase
activates downstream signaling pathways involved in morphogenic, proliferative, and antiapoptotic processes [1].
Aberrant MET activation can be triggered by MET amplification as well as a range of MET mutations, including exon
14 skipping mutations that result in constitutive activation
of MET [2]. Overexpression of MET or heightened MET
activity can contribute to tumor progression by promoting
tumor cell survival, proliferation and migration, epithelialmesenchymal transition (EMT), and angiogenesis [3]. MET
exon 14 skipping mutations and amplification are reported
in patients with non-small cell lung cancer (NSCLC) and
are also observed at varying incidences across other solid
tumors, including, but not limited to, colon cancer, gastric
cancer, prostate cancer, and renal cell carcinoma [4–6].
Importantly, tumors with MET amplification and MET exon
14 skipping alterations are associated with poor prognosis
[7].
Aberrant MET activation has been identified as a mechanism of resistance to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs). This occurs by
activating EGFR-independent phosphorylation of ErbB3 and
the PI3K/AKT pathway, providing a bypass resistance mechanism [8, 9]. Consequently, co-targeting EGFR and MET has
the potential to prevent this crosstalk and overcome resistance in some patients. This is supported by a phase 1b study
in which partial responses (PRs) were observed in patients
with MET-amplified NSCLC treated with the EGFR TKI
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osimertinib, and savolitinib, an MET TKI [10]. Activation
of other bypass signaling pathways has also been implicated
in resistance to EGFR TKIs, including ErbB2, fibroblast
growth factor receptor, insulin-like growth factor 1 receptor, and AXL [11]. High expression of AXL has been linked
with tumor growth, EMT, and metastasis and is associated
with poor prognosis in a range of tumors, including lung
cancer [12–18]. Furthermore, in NSCLC cells, AXL has
been shown to interact with EGFR and HER3 and maintain
cell survival following exposure to EGFR TKIs. Moreover,
in in vivo models, an AXL inhibitor plus EGFR TKI reduced
tumor size and delayed tumor regrowth compared with an
EGFR TKI alone [19].
Glesatinib (MGCD265) is an investigational receptor
TKI of mutant and wild-type forms of MET, along with
AXL, MER proto-oncogene tyrosine kinase (MERTK), vascular endothelial growth factor receptor (VEGFR), and the
platelet-derived growth factor receptor (PDGFR) family in
preclinical studies [20]. At clinically achievable doses, MET
and AXL were identified as the most relevant glesatinib
targets based on pharmacodynamic and preliminary clinical data [20]. Single-agent glesatinib was shown to induce
robust tumor regression in patient-derived NSCLC xenograft
models with MET exon 14 deletion and MET amplification
as putative oncogenic drivers [20]. The present study investigated the safety profile of glesatinib, across different formulations based on emerging data, in combination with the
EGFR TKI erlotinib or the frequently used taxane docetaxel,
in patients with advanced solid tumors. The antitumor activity of these treatment combinations was also evaluated in
patients with advanced solid tumors who were not genetically selected for MET/AXL alterations such as skipping
mutations or amplification, or expression.

2 Methods
2.1 Study Design and Patient Population
This open-label, multicenter study evaluated glesatinib in
combination with erlotinib or docetaxel. We enrolled nongenetically selected patients ≥ 18 years of age with histologically or cytologically confirmed advanced metastatic or
unresectable solid malignancy that was refractory to standard therapy/unlikely to achieve clinical benefit, or who had
declined standard therapy. All patients had documented
progressive disease (PD) during or following their most
recent treatment, and evaluable disease (either measurable
or non-measurable by Response Evaluation Criteria in Solid
Tumors [RECIST] v1.1). Patients also had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
and adequate renal, hepatic and bone marrow function. Key
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exclusion criteria were anticancer treatment within 4 weeks
of the first study treatment; prior treatment with a MET
inhibitor or anti-HGF therapy; uncontrolled concurrent illness including serious infection, hypertension or endocrine
disease; stroke or transient ischemic attack in the prior 6
months; history of bleeding diathesis, coagulopathy or cardiovascular illness; and QT interval corrected for heart rate
(QTc) > 470 ms.
While there were no genetic selection criteria for the
phase I dose-escalation cohorts, enrollment focused on
patients with specific cancer types (including NSCLC,
prostate cancer, gastric cancer) and patients with other solid
tumors typically associated with MET alterations such as
skipping mutations or amplification, or AXL overexpression.
The phase I portion of the study (modified 3 + 3 design)
included two parallel arms in which ascending doses of
oral glesatinib (starting dose 96 mg/m2) were administered
with either erlotinib or docetaxel (treatment assignment was
based on the investigator’s judgment) at starting doses of
100 mg once daily and 50 mg/m2 every 3 weeks, respectively. Glesatinib was administered either once daily or twice
daily, either fasted (no food for 2 h prior to or 1 h after dosing) or with food, depending on the cohort, and was initially
supplied as an unmicronized glycolate formulation. Based
on available data during the study, a micronized glesatinib
glycolate formulation was provided followed by a version 2
(V2) micronized tablet containing sodium lauryl sulphate,
aimed at improving the consistency of particle size and
absorption, respectively.
If no dose-limiting toxicities (DLTs; defined below) were
observed in the first patient cohort during Cycle 1, a new
cohort of three or four patients was enrolled at dose level
2 (glesatinib 96 mg/m2 plus erlotinib 150 mg once daily or
docetaxel 75 mg/m2 every 3 weeks) (Fig. 1). If one of three
or four patients experienced a DLT at dose level 1 then up
to four additional patients were to be enrolled at that dose
level, and if one or fewer of six of these patients experienced
a DLT then a new cohort was enrolled (at dose level 2). Subsequent dose escalations are described in Fig. 1. If ≥ 33% of
six or more patients experienced a DLT at any dose level, the
maximum tolerated dose (MTD) would be exceeded. Study
treatment (21-day cycles) was continued until unacceptable
toxicity, disease progression/recurrence, or withdrawal of
consent. Dose modifications of glesatinib, erlotinib, or docetaxel were permitted for adverse events (AEs) considered
related to study medication.
Phase I expansion cohorts were planned at the MTD or
maximum administered dose (MAD) in each study arm in
patients genetically selected for MET and/or AXL alterations, along with a phase II randomized portion of the study,
investigating glesatinib plus erlotinib versus glesatinib plus
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docetaxel in patients with MET and/or AXL altered NSCLC,
but were not conducted (see below).
The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation
Guidelines for Good Clinical Practice, and local regulatory
requirements. The study protocol was approved by the Institutional Review Boards at each participating study site.

2.2 Study Endpoints and Assessments
The phase I primary objective was to determine the safety
profile of glesatinib in combination with erlotinib or docetaxel, including the MTD/MAD and DLTs. Evaluation of
antitumor activity and pharmacokinetics (PK) of glesatinib plus erlotinib or docetaxel were included as secondary
objectives.
Safety assessment included evaluation of AEs, graded
according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0,
laboratory assessments, physical examinations, vital signs,
and electrocardiograms/multiple gated acquisition scans.
DLTs were defined as any of the following AEs occurring
during Cycle 1 that were considered possibly, probably,
or definitely related to glesatinib: Grade 4 neutropenia for
≥ 7 days; Grade 3 or higher febrile neutropenia; Grade 4
thrombocytopenia (or anemia or bleeding episode requiring
platelet transfusion); Grade 3 or higher clinically significant,
non-hematologic toxicity unrelated to the underlying malignancy; severe hypertension (≥ 180/120 mmHg); sustained
uncontrolled hypertension (150–179/100–119 mmHg for ≥
14 days or causing a treatment delay of ≥ 4 days); and any
toxicity other than Grade 3 neutropenia that resulted in a
treatment delay of ≥ 6 or ≥ 12 doses of glesatinib administered on once-daily or twice-daily schedules, respectively,
that was of sufficient severity to be considered a DLT.
Tumor evaluations using magnetic resonance imaging
or computed tomography scans were performed every two
cycles. Progression-free survival (PFS) was assessed using
Kaplan–Meier methodology (time from first study treatment to first documented disease progression or death), and
objective response rate (ORR) was evaluated per RECIST
v1.1 and/or other appropriate criteria [21]. Blood samples
for PK assessments were obtained during Cycle 1 (days 1, 2,
3, and 8) and Cycle 2 (days 1, 2, and 3); day 1 PK samples
were obtained at five timepoints in both cycles. Analysis of
plasma samples for glesatinib, erlotinib, and docetaxel concentrations were performed using validated methods.

2.3 Statistical analysis
For the phase I dose escalation, enrollment of approximately
60–90 patients was planned for the glesatinib + erlotinib
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(a)
Dose escalation 1
3 or 4 patients
• Glesatinib same
• Erlotinib 150 mg

Starting dose

0 DLT

3 or 4 patients
• Glesatinib 96 mg/m2
• Erlotinib 100 mg

1 DLT

0/3 or
1/6 DLT

1/3 DLT

Add patients for n≥6
• Glesatinib same
• Erlotinib same

>1 DLT
3 or 4 patients
• Glesatinib 33% reduction
• Erlotinib same

3 or 4 patients
• Glesatinib 96 mg/m2
• Docetaxel 50 mg/m2

2/3 or
2/6 DLT

Dose escalation 1
3 or 4 patients
• Glesatinib same
• Docetaxel 75 mg/m2

Starting dose

0 DLT

1 DLT

3 or 4 patients
• Glesatinib 50% increasea
• Erlotinib 150 mg

1/6 DLT

≥2/6 DLT

(b)

Subsequent dose escalations

Add patients for n≥6
• Glesatinib same
• Erlotinib 150 mg

MTD exceeded
Consider 3 or 4 patients
• Glesatinib 33% reduction
• Erlotinib 150 mg

Subsequent dose escalations

0/3 or
1/6 DLT

3 or 4 patients
• Glesatinib 50% increasea
• Docetaxel 75 mg/m2

1/6 DLT
1/3 DLT

Add patients for n≥6
• Glesatinib same
• Docetaxel same
≥2/6 DLT

>1 DLT
3 or 4 patients
• Glesatinib 33% reduction
• Docetaxel same

2/3 or
2/6 DLT

Add patients for n≥6
• Glesatinib same
• Docetaxel 75 mg/m2

MTD exceeded
Consider 3 or 4 patients
• Glesatinib 33% reduction
• Docetaxel 75 mg/m2

Fig. 1  Dose escalation schemes. a Glesatinib plus erlotinib; b glesatinib plus docetaxel. aIf no Grade 2 or higher treatment-related adverse
events had occurred at that dose level or at any prior dose level, the

glesatinib dose could be increased by more than 50% (but not >
100%) following agreement by the study investigators and sponsor.
DLT dose-limiting toxicity, MTD maximum tolerated dose

arm. Approximately 60–90 patients were also planned for
the glesatinib + docetaxel arm.
Data were summarized using descriptive statistics.
Safety was evaluated in all patients who received one or
more doses of any study drug. DLTs were evaluated in
patients who received ≥ 70% of the planned glesatinib
dose and either ≥ 70% of the planned erlotinib dose or
the single planned intravenous administration of docetaxel during Cycle 1 and who were evaluable for toxicity throughout Cycle 1 or experienced a DLT. Efficacy is
presented for patients who received one or more doses of
glesatinib and erlotinib/docetaxel and had one or more onstudy disease assessments. PK were assessed in all patients
with sufficient concentration–time data and analyzed by

nonc ompartmental methods using Phoenix WinNonlin
v6.2.1 (Pharsight Corporation, St Louis, MO, USA).

3 Results
3.1 Patient Characteristics and Disposition
In total, 126 patients were recruited into the Phase I portion of the study between 15 August 2009 and 15 July
2013, with n = 69 and n = 57, respectively, for the combinations of glesatinib + erlotinib and glesatinib + docetaxel. The study was closed prematurely prior to enrollment of the phase I dose expansion and the phase II
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(a)
Cohorts
• Fasted
• Glesatinib tablet: unmicronized + micronized

Cohorts
• Fasted
• Glesatinib tablet: version 2 micronized

Cohorts
• Fed
• Glesatinib tablet: version 2 micronized

Subjects enrolled (N=34)
• Received allocated intervention (n=34)

Subjects enrolled (N=14)
• Received allocated intervention (n=14)

Subjects enrolled (N=21)
• Received allocated intervention (n=21)

Reasons for study withdrawal
• Disease progression / recurrencea (n=27, 79.4%)
• AE (n=1, 2.9%)
• Concurrent illness (n=0)
• Investigator/sponsor decision (n=3, 8.8%)
• Symptomatic deteriorationb (n=1, 2.9%)
• Patient decision (n=2, 5.9%)

Reasons for study withdrawal
• Disease progression / recurrencea (n=7, 50.0%)
• AE (n=2, 14.3%)
• Concurrent illness (n=0)
• Investigator/sponsor decision (n=0)
• Symptomatic deteriorationb (n=2, 14.3%)
• Patient decision (n=3, 21.3%)

Reasons for study withdrawal
• Disease progression / recurrencea (n=10, 47.6%)
• AE (n=3, 14.3%)
• Concurrent illness (n=1, 4.8%)
• Investigator/sponsor decision (n=2, 9.5%)
• Symptomatic deteriorationb (n=2, 9.5%)
• Patient decision (n=3, 14.3%)

Cohorts
• Fasted
• Glesatinib tablet: unmicronized + micronized

Cohorts
• Fasted
• Glesatinib tablet: version 2 micronized

Cohorts
• Fed
• Glesatinib tablet: version 2 micronized

Subjects enrolled (N=24)
• Received allocated intervention (n=24)

Subjects enrolled (N=17)
• Received allocated intervention (n=17)

Subjects enrolled (N=16)
• Received allocated intervention (n=16)

Reasons for study withdrawal
• Disease progression / recurrencea (n=14, 58.3%)
• AE (n=2, 8.3%)
• Concurrent illness (n=0)
• Investigator/sponsor decision (n=3, 12.5%)
• Symptomatic deteriorationb (n=2, 8.3%)
• Patient decision (n=3, 12.5%)

Reasons for study withdrawal
• Disease progression / recurrencea (n=10, 58.8%)
• AE (n=3, 17.6%)
• Concurrent illness (n=0)
• Investigator/sponsor decision (n=2, 11.8%)
• Symptomatic deteriorationb (n=0)
• Patient decision (n=2, 11.8%)

Reasons for study withdrawal
• Disease progression / recurrencea (n=9, 56.3%)
• AE (n=1, 6.3%)
• Concurrent illness (n=0)
• Investigator/sponsor decision (n=2, 12.5%)
• Symptomatic deteriorationb (n=1, 6.3%)
• Patient decision (n=3, 18.8%)

(b)

Fig. 2  Patient disposition. a Glesatinib plus erlotinib; b glesatinib
plus docetaxel. aPer RECIST version 1.1 (patients with prior response
or stable disease recorded in efficacy evaluations may discontinue due
to disease progression reported at a later timepoint). bGlobal deterio-

ration in health status without objective evidence of disease progression per RECIST version 1.1. AE adverse event, RECIST Response
Evaluation Criteria in Solid Tumors

randomized portions of this study due to the planned reformulation of glesatinib. Most patients discontinued due to disease
progression (glesatinib + erlotinib, n = 44 [63.8%]; glesatinib
+ docetaxel, n = 33 [57.9%]) and few discontinued due to
AEs (n = 6 [8.7%]; n = 6 [10.5%]) (Fig. 2).
Baseline demographic and disease characteristics were
similar across the two phase I cohorts (Table 1). Median
age was 61.9 and 61.6 years in the glesatinib + erlotinib and
glesatinib + docetaxel cohorts, respectively. Approximately
half the patients were never smokers and had an ECOG performance status of 1. Nearly all patients had received prior
chemotherapy and approximately half had received radiotherapy. The most frequent cancer diagnoses were NSCLC,
colon cancer, pancreatic cancer, and gastric cancer (Table 1).

administration, erlotinib/docetaxel dose, and whether study
treatment was administered in a fasted or fed state (Table 2).
In the glesatinib + erlotinib arm, dose escalation proceeded through 10 dose levels of glesatinib across the three
formulations. As one of three patients experienced a DLT
of Grade 3 diarrhea (probably related to glesatinib and erlotinib) in the first cohort of glesatinib 96 mg/m2 once daily
(unmicronized), this was expanded to six evaluable patients
and no further DLTs were observed. Acneiform rash and
fatigue (both Grade 3 and considered related to glesatinib
and erlotinib) were observed in two patients enrolled in
the glesatinib 144 mg/m2 once daily (micronized) cohort;
the cohort was expanded with no further DLTs reported.
DLTs were also seen with glesatinib micronized V2 tablets
108 mg/m2 twice daily (Grade 3 diarrhea, related to glesatinib and erlotinib) and 162 mg/m2 twice daily (diarrhea
and rhabdomyolysis; both Grade 3 and related to glesatinib
and erlotinib). No DLTs were observed with fixed doses of
glesatinib (V2 micronized) 250 mg once daily, 500 mg once
daily, or 500 mg twice daily + erlotinib. The final dose level

3.2 Dose Escalation and Dose‑Limiting Toxicities
In each study arm, 14 dosing cohorts were investigated
based on the formulation (unmicronized, micronized, or
micronized V2 tablets), dose and frequency of glesatinib
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Table 1  Baseline demographic and disease characteristics (safety population)

Age, years [median (range)]
Male
ECOG performance status
0
1
Never smoker
Cancer diagnosisa
NSCLC
Colon cancer
Pancreatic carcinoma
Gastric cancer
Pancreatic adenocarcinoma
Esophageal adenocarcinoma
Rectal cancer
Liver cancer
Prostate cancer
Bladder cancer
Transitional cell carcinoma
Prior cancer treatment
Chemotherapy
Surgery
Radiation
Hormonal therapy
Other
Months from cancer diagnosis to first dose of study medication [mean (SD)]
Months from the most recent recurrence/relapse to first dose of study medication
[mean (SD)]

Glesatinib + erlotinib
[N = 69]

Glesatinib + docetaxel
[N = 57]

61.9 (32.6–84.1)
39 (56.5)

61.6 (46.2–81.4)
32 (56.1)

31 (44.9)
38 (55.1)
38 (55.1)

29 (50.9)
28 (49.1)
23 (40.4)

10 (14.5)
14 (20.3)
3 (4.3)
5 (7.2)
6 (8.7)
4 (5.8)
5 (7.2)
4 (5.8)
0
1 (1.4)
0

16 (28.1)
0
7 (12.3)
2 (3.5)
0
2 (3.5)
0
0
4 (7.0)
2 (3.5)
3 (5.3)

66 (95.7)
40 (58.0)
38 (55.1)
0
15 (21.7)
44.3 (47.7)
14.3 (16.5)

51 (89.5)
30 (52.6)
30 (52.6)
4 (7.0)
18 (31.6)
36.3 (31.1)
12.6 (17.3)

Data are expressed as n (%) unless otherwise specified
ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung cancer, SD standard deviation
a

Reported for three or more patients

and MAD in this treatment arm was glesatinib 700 mg (V2
micronized) twice daily with food + erlotinib 150 mg once
daily, at which two of five DLT-evaluable patients experienced DLTs of Grade 3 diarrhea (both considered related to
glesatinib and erlotinib) (Table 2).
Dose escalation of glesatinib + docetaxel also proceeded through 10 glesatinib dose levels across the three
formulations. No DLTs were observed with glesatinib
(unmicronized and micronized formulations) at doses up
to 144 mg once daily in combination with docetaxel. Following DLTs of Grade 3 diarrhea (related to glesatinib
and docetaxel) and Grade 3 elevated lipase (related to
glesatinib) in the first patient who received glesatinib 96
mg/m 2 twice daily (micronized) + docetaxel 75 mg/m 2
every 3 weeks, and a DLT of Grade 3 fatigue in the second
patient in this cohort, the MTD of micronized glesatinib
(micronized) + docetaxel was considered exceeded. With

glesatinib micronized V2 tablets, no DLTs were observed
at doses of 48–170 mg/m2 twice daily or a 300 mg twicedaily fixed dose. A DLT of elevated aspartate aminotransferase (AST; considered related to docetaxel) was observed
in one of six patients in the glesatinib 450 mg twice daily
cohort, and at the MAD of glesatinib 700 mg twice daily
(V2 micronized) + docetaxel 75 mg/m2 every 3 weeks, two
of six DLT-evaluable patients experienced DLTs: Grade
2 acute pancreatitis (considered related to glesatinib and
unrelated to docetaxel) and Grade 3 elevated AST (considered related to glesatinib and docetaxel) (Table 2).
While the MADs of glesatinib (V2 micronized) 700
mg twice daily in combination with erlotinib 150 mg once
daily or docetaxel 75 mg/m2 every 3 weeks exceeded the
MTD in both study arms, evaluation of MTD did not
proceed due to termination of the study (further MTD

131

Phase I Study of Glesatinib Plus Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
Table 2  Dose-limiting toxicities across the glesatinib dosing cohorts
Cohort

Glesatinib dose
and formulation

Fed or fasting

Received study medication (DLT evaluable), n

Glesatinib glycolate + erlotinib (100 mg qd in Cohort 1 and 150 mg qd in Cohorts 2–14)
Fasting
8 (6)
1
96 mg/m2 qd
Unmicronized
2
96 mg/m2 qd
Fasting
6 (4)
Unmicronized
3
96 mg/m2 qd
Fasting
4 (3)
Micronized
4
144 mg/m2 qd
Fasting
9 (9)
Micronized
5
6
7
8
9

72 mg/m2 bid
Unmicronized
108 mg/m2 bid
Unmicronized
72 mg/m2 bid
Micronized V2
108 mg/m2 bid
Micronized V2
162 mg/m2 bid
Micronized V2

Observed DLTsa
Relationship to study medication
Diarrhea (Grade 3, n = 1)
Related to glesatinib and erlotinib
0
0

Fasting

4 (4)

Acneiform rash (Grade 3, n = 1)
Related to glesatinib and erlotinib
Fatigue (Grade 3, n = 1)
Related to glesatinib and erlotinib
0

Fasting

3 (3)

0

Fasting

3 (3)

0

Fasting

4 (4)

Fasting

7 (4)

Diarrhea (Grade 3, n = 1)
Related to glesatinib and erlotinib
Diarrhea (Grade 3, n = 1)
Related to glesatinib and erlotinib
Rhabdomyolysis (Grade 3, n = 1)
Related to glesatinib and erlotinib
0

75 mg/m2 qd
Fed
3 (3)
Micronized V2
11
250 mg qd
Fed
4 (3)
0
Micronized V2
12
500 mg qd
Fed
3 (3)
0
Micronized V2
13
500 mg bid
Fed
4 (4)
0
Micronized V2
14
700 mg bid
Fed
7 (5)
Diarrhea (Grade 3, n = 2)
Micronized V2
Related to glesatinib and erlotinib (both events)
Glesatinib glycolate + docetaxel (50 mg/m2 q3w in Cohort 1 and 75 mg/m2 q3w in Cohorts 2–14)
Fasting
3 (3)
0
1
96 mg/m2 qd
Unmicronized
2
96 mg/m2 qd
Fasting
4 (3)
0
Unmicronized
3
144 mg/m2 qd
Fasting
4 (3)
0
Unmicronized
4
144 mg/m2 qd
Fasting
4 (4)
0
Micronized
5
96 mg/m2 bid
Fasting
2 (2)
Fatigue (Grade 3, n = 1)
Micronized
Related to glesatinib and docetaxel
Diarrhea (Grade 3, n = 1)b
Related to glesatinib and docetaxel
Lipase increased (Grade 3, n = 1)b
Related to glesatinib
2
Fasting
7 (7)
Lipase increased (Grade 3, n = 1)
6
72 mg/m bid
Unmicronized
Related to glesatinib
7
48 mg/m2 bid
Fasting
3 (3)
0
Micronized V2
8
72 mg/m2 bid
Fasting
3 (3)
0
Micronized V2
10
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Table 2  (continued)
Cohort
9
10
11
12
13
14

Glesatinib dose
and formulation
96 mg/m2 bid
Micronized V2
128 mg/m2 bid
Micronized V2
170 mg/m2 bid
Micronized V2
300 mg bid
Micronized V2
450 mg bid
Micronized V2
700 mg bid
Micronized V2

Fed or fasting

Received study medication (DLT evaluable), n

Observed DLTsa
Relationship to study medication

Fasting

4 (3)

0

Fasting

3 (3)

0

Fasting

4 (4)

0

Fed

4 (4)

0

Fed

6 (6)

Fed

6 (6)

AST increased (Grade 3, n = 1)
Related to docetaxel
AST increased (Grade 3, n = 1)
Unrelated to glesatinib and docetaxel
Acute pancreatitis (Grade 2, n = 1)c
Related to glesatinib

AST aspartate aminotransferase, bid twice daily, DLT dose-limiting toxicity, qd once daily, q3w once every 3 weeks, V2 version 2 formulation
(contained sodium lauryl sulphate), NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events

a

b
c

NCI-CTCAE grade; ‘related’ includes ‘definitely’, ‘probably’, and ‘possibly’ related to study treatment per investigator assessment
Observed in the same patient
Event resulted in study discontinuation and was determined as a DLT by the investigator, in consultation with the sponsor

evaluations were planned using reformulated glesatinib,
as described below).

3.3 Safety
Median (range) duration of study treatment was 1.3 months
(0 days to 28.0 months) and 1.3 months (1 day to 18.1
months) in the glesatinib + erlotinib and glesatinib + docetaxel groups, respectively, with approximately half of the
patients (50.7% and 52.6%, respectively) completing only
one cycle of treatment. The mean (standard deviation) relative dose intensity of glesatinib was 90.7% (16.7%) and
89.6% (16.9%) in the glesatinib + erlotinib and glesatinib +
docetaxel groups, respectively.
The most frequent treatment-emergent AEs were diarrhea (glesatinib + erlotinib: 80.7% [n = 60]; glesatinib
+ docetaxel: 49.1% [n = 28]), fatigue (59.4% [n = 41];
75.4% [n = 43]), neutropenia (0; 64.9% [n = 37]), alopecia (0; 49.1% [n = 28]), and nausea (40.6% [n = 28];
40.4% [n = 23]). These AEs were frequently considered
related to study treatment (Table 3). Across the study, 42
patients experienced 64 treatment-emergent serious AEs
(SAEs), of which disease progression was most frequent
(glesatinib + erlotinib: 11.6% [n = 8]; glesatinib + docetaxel: 5.3% [n = 3]). Other treatment-emergent SAEs
occurring in two or more patients were gastrointestinal hemorrhage, pneumonia, and pulmonary embolism (glesatinib
+ erlotinib, each n = 2 [2.9%]) and febrile neutropenia (glesatinib + docetaxel: n = 2 [3.5%]). Laboratory results were
unremarkable. Increased QTc (≥30 msec from baseline)

was observed in eight patients (14.0%) receiving glesatinib
+ docetaxel, ranging from 30.8 to 38.6 msec, and was not
considered clinically significant. Left ventricular ejection
fraction decline was observed in two patients (2.9%) receiving glesatinib + erlotinib (screening to study end: 55 to 36%
[reported as a treatment-related SAE in an individual with
a history of coronary disease] and 57 to 41% [not reported
as an AE]). Thirteen patients (10.3%) died within 28 days
of receiving the last dose of study medication: 12 deaths
were considered unrelated to study medication (n = 11 disease progression, n = 1 cardiorespiratory arrest), while one
death due to pneumonitis was considered possibly related
to study medication and occurred in a patient with NSCLC
receiving glesatinib + docetaxel (1.8%) who had dyspnea
and decreased right lung breath sounds, ongoing since study
enrollment.

3.4 Efficacy
Of the patients who received glesatinib + erlotinib, ORR
was 1.8%. One PR (duration of 6 months with fasted glesatinib 72 mg/m2 twice daily + erlotinib 150 mg in an individual with NSCLC) was reported among the 50 patients with
measurable disease at baseline (there were no responses in
the seven patients with non-measurable disease at baseline).
Stable disease (SD) was observed in 27 patients (47.4%),
while 22 patients (38.6%) had disease progression (PD). Of
the patients who received glesatinib + docetaxel, ORR was
12.0%. PRs were observed in 6 of 49 patients with measurable disease at baseline (NSCLC, n = 2; urothelial cancer,
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Table 3  AEs (NCI-CTCAE grade) considered related to study treatment (any AE considered ‘unknown’, ‘possibly’, ‘probably’ or ‘definitely’
related to any study drug) occurring in ≥10% of patients (safety population)
MedDRA preferred term

Diarrhea
Fatigue
Nausea
Rash
Neutropenia
Anorexia
Alopecia
Vomiting
Dysgeusia
Mucosal inflammation
Hypokalemia
Dermatitis acneiform
Dry skin

Glesatinib + erlotinib
[N = 69]

Glesatinib + docetaxel
[N = 57]

All grades

Grade 3 or 4

All grades

Grade 3 or 4

58 (84.1)
32 (46.4)
21 (30.4)
30 (43.5)
0
20 (29.0)
0
9 (13.0)
8 (11.6)
6 (8.7)
10 (14.5)
14 (20.3)
10 (14.5)

12 (17.4)
1 (1.4)
0
1 (1.4)
0
0
0
0
0
0
4 (5.8)
1 (1.4)
0

26 (45.6)
40 (70.2)
20 (35.1)
8 (14.0)
37 (64.9)
16 (28.1)
28 (49.1)
13 (22.8)
13 (22.8)
10 (17.5)
5 (8.8)
0
4 (7.0)

4 (7.0)
1 (1.8)
0
0
37 (64.9)
0
0
0
0
0
2 (3.5)
0
0

Data are expressed as n (%)
AEs adverse events, MedDRA Medical Dictionary for Regulatory Activities, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events

nasopharyngeal cancer, prostate cancer, endometrial cancer, n = 1 each; median [range] duration of response was
2.8 months [1 day to 10.6 months]; there was no response in
one patient with non-measurable disease). SD was reported
in 24 patients (48.0%) and PD in 19 patients (38.0%).
Median (95% confidence interval) PFS was 2.5 months
(1.4–3.7) and 3.1 months (1.5–4.4) for the glesatinib + erlotinib and glesatinib + docetaxel groups, respectively.

3.5 Pharmacokinetics
Following multiple doses of glesatinib with docetaxel or
erlotinib under fasted or fed conditions, after reaching maximum plasma concentration (Cmax), plasma glesatinib concentration declined slowly. The median time to reach Cmax
(tmax) was observed 1–11 h postdose, and mean peak-totrough ratios were approximately 0.9–3.4 across all cohorts
under fasted conditions. Bioavailability was limited, with
systemic exposure to glesatinib tending to increase in a less
than dose proportional manner at higher doses, and there
was no evidence to suggest improved absorption or bioavailability was associated with a particular formulation of
glesatinib. Food did not appear to impact the PK parameters
of glesatinib: Cmax and area under the plasma concentration–time curve from time zero to 12 h (AUC12) values were
comparable in fed and fasted cohorts receiving glesatinib V2
tablets twice daily (with erlotinib or docetaxel). While high
interpatient variability was observed, there was no evidence
that increasing the dose of erlotinib or docetaxel impacted

glesatinib PK parameters, or vice versa. Plasma PK parameters for glesatinib in combination with erlotinib and docetaxel are summarized Tables 4 and 5, respectively.

4 Discussion
This study examined the potential utility of combining glesatinib, an investigational TKI of MET and AXL at clinically
relevant doses, with erlotinib and separately with docetaxel.
Glesatinib was evaluated across different glycolate formulations (unmicronized, micronized, and micronized V2 tablets)
and at differing dose levels.
The tolerability of glesatinib in combination with erlotinib or docetaxel was acceptable and no safety concerns
were identified that were considered likely to impact further
clinical development. Across the treatment cohorts, diarrhea (glesatinib + erlotinib: 84.1%; glesatinib + docetaxel:
45.6%), fatigue (46.4%; 70.4%), nausea (30.4%; 35.1%), and
rash (43.5%; 14.0%) were the most frequent AEs considered related to any study treatment, broadly in line with the
anticipated safety profile of these treatment combinations.
PK data revealed glesatinib concentrations were comparable between the fed and fasted cohorts receiving glesatinib
micronized V2, indicating a lack of food effect, facilitating
convenient timing for twice-daily dosing. Furthermore, there
was no evidence of drug–drug interactions with glesatinib
and erlotinib or docetaxel, suggesting glesatinib may have
the potential to be combined with other cytotoxic agents.
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Table 4  Pharmacokinetic parameters for glesatinib in combination with erlotinib (erlotinib dose was 100 mg qd in cohort 1 and 150 mg qd in
cohorts 2–14) during cycle 2, day 1
Cohort

Glesatinib dose and
formulation

Statistic

Glesatinib qd under fasted conditions
Mean
1
96 mg/m2 qd
Unmicronized
SD
n
2
96 mg/m2 qd
Mean
Unmicronized
SD
n
3
96 mg/m2 qd
Mean
Micronized
SD
n
2
4
144 mg/m qd
Mean
Micronized
SD
n
Glesatinib bid under fasted conditions
5
72 mg/m2 bid
Mean
Unmicronized
SD
n
6
108 mg/m2 bid
Mean
Unmicronized
SD
n
7
72 mg/m2 bid
Mean
Micronized V2
SD
n
8
108 mg/m2 bid
Mean
Micronized V2
SD
n
9
162 mg/m2 bid
Mean
Micronized V2
SD
n
Glesatinib qd under fed conditions
10
75 mg/m2 qd
Mean
Micronized V2
SD
n
11
250 mg qd
Mean
Micronized V2
SD
n
12
500 mg qd
Mean
Micronized V2
SD
n
Glesatinib bid under fed conditions
13
500 mg bid
Mean
Micronized V2
SD
n
14
700 mg bid
Mean
Micronized V2
SD
n

Cmax (ng/mL)

tmaxa (h)

AUC12b
(ng·h/mL)

CLss/F (L/h)

Cmax/Ctrough ratio

59.3
25.5
6
58.4
34.6
4
56.8
26.9
4
51.8
21.8
7

4.0
(3.0–10.0)
6
7.5
(5.0–24.0)
4
3.0
(3.0–5.0)
4
5.0
(1.0–5.0)
7

1080
443
6
1143
792
4
1160
529
4
975
488
7

208
74.7
6
207
126
4
212
123
4
358
144
7

2.56
1.36
6
3.38
3.86
4
1.49
0.116
4
1.75
0.502
7

48.0
38.0
4
60.5
NC
2
62.0
21.2
3
59.3
32.2
3
90.6
41.3
3

2.0
(1.0–10.0)
4
5.5
(1.0–10.0)
2
5.0
(3.0–12.0)
3
5.0
(1.0–10.0)
3
1.0
(1.0–3.0)
3

529
416
4
690
NC
2
629
177
3
452
NC
2
937
422
3

500
449
4
513
NC
2
253
78.6
3
485
NC
2
389
232
3

1.00
0.068
4
0.937
NC
2
1.28
0.417
3
1.09
0.077
3
0.99
0.241
3

50.8
3.64
3
39.0
24.6
3
94.4
14.5
3

24.0
(5.0–24.0)
3
9.0
(1.0–12.0)
3
12.0
(10.0–24.0)
3

1018
72.7
3
846
538
3
1935
393
3

131
56.3
3
403
272
3
265
53.0
3

1.36
0.361
3
1.22
0.356
3
1.34
0.114
3

183
51.5
4
111
NC
1

7.5
(5.0–10.0)
4
5.0
(5.0–5.0)
1

1916
412
4
1290
NC
1

269
53.3
4
543
NC
1

1.15
0.044
4
1.18
NC
1

AUC12/24 area under the plasma concentration–time curve from time zero to 12 or 24 h after dosing, bid twice daily, CLss/F apparent clearance
after multiple oral administrations, Cmax maximum plasma concentration, Ctrough predose plasma concentration, NC not calculated, qd once daily,
SD standard deviation, tmax time to maximum observed plasma concentration
a

b

Median and range reported for tmax

AUC24 reported for cohorts 1–4 and cohorts 10–12
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Table 5  Pharmacokinetic parameters for glesatinib in combination with docetaxel (docetaxel dose was 50 mg/m2 q3w in cohort 1 and 75 mg/m2
q3w in cohorts 2–14) during cycle 2, day 1
Cohort

Glesatinib dose and
formulation

Statistic

Glesatinib qd under fasted conditions
Mean
1
96 mg/m2 qd
Unmicronized
SD
n
2
96 mg/m2 qd
Mean
Unmicronized
SD
n
3
144 mg/m2 qd
Mean
Unmicronized
SD
n
2
4
144 mg/m qd
Mean
Micronized
SD
n
Glesatinib bid under fasted conditions
5
96 mg/m2 bid
Mean
Micronized
SD
n
6
72 mg/m2 bid
Mean
Unmicronized
SD
n
7
48 mg/m2 bid
Mean
Micronized V2
SD
n
8
72 mg/m2 bid
Mean
Micronized V2
SD
n
9
96 mg/m2 bid
Mean
Micronized V2
SD
n
10
128 mg/m2 bid
Mean
Micronized V2
SD
n
2
11
170 mg/m bid
Mean
Micronized V2
SD
n
Glesatinib bid under fed conditions
12
300 mg bid
Mean
Micronized V2
SD
n
13
450 mg bid
Mean
Micronized V2
SD
n
14
700 mg bid
Mean
Micronized V2
SD
n

Cmax (ng/mL)

tmaxa (h)

AUC12b
(ng·h/mL)

CLss/F (L/h)

Cmax/Ctrough ratio

83.5
11.9
3
74.7
30.8
3
67.3
58.5
3
99.7
41.7
3

3.0
(2.0–5.0)
3
5.0
(3.0–5.0)
3
7.0
(3.0–7.0)
3
2.0
(2.0–24.0)
3

1574
137
3
1207
443
3
1120
928
3
1643
861
3

128
11.1
3
157
85.2
3
407
355
3
182
57.3
3

1.74
0.475
3
2.51
0.799
3
2.37
0.860
3
1.56
0.465
3

64.7
NC
1
84.2
45.8
6
58.9
24.3
3
96.3
23.8
3
62.6
48.0
3
93.3
NC
2
119
48.5
4

11.0
(11.0–11.0)
1
4.0
(2.0–5.0)
6
2.0
(2.0–2.0)
3
1.0
(1.0–2.0)
3
7.0
(2.0–12.0)
3
2.0
(1.0–3.0)
2
2.0
(1.0–5.0)
4

488
NC
1
828
430
6
602
246
3
854
162
3
578
394
3
922
NC
2
1122
441
4

410
NC
1
241
226
6
184
66.8
3
138
27.1
3
546
528
3
403
NC
2
330
148
4

120
NC
1
1.43
0.302
6
1.12
0.098
3
1.19
0.058
3
1.24
NC
2
1.23
NC
2
1.30
0.363
4

205
77.2
4
132
74.6
5
141
53.0
4

2.0
(1.0–12.0)
4
5.0
(1.0–12.0)
5
6.0
(2.0–7.0)
4

2105
800
4
1190
824
5
1547
554
4

162
72.2
4
503
255
5
528
284
4

1.14
0.164
4
21.2
37.9
5
1.11
0.433
4

AUC12/24 area under the plasma concentration–time curve from time zero to 12 or 24 h after dosing, bid twice daily, CLss/F apparent clearance
after multiple oral administrations, Cmax maximum plasma concentration, Ctrough predose plasma concentration, NC not calculated, q3w once
every 3 weeks, qd once daily, SD standard deviation, tmax time to maximum observed plasma concentration
a

b

Median and range reported for tmax
AUC24 reported for cohorts 1–4
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Despite activating MET alterations or AXL overexpression not being inclusion criteria for this phase I study that
focused on safety, modest signals of efficacy were observed,
with PRs of 1.8% and 12.0% in the glesatinib + erlotinib and
glesatinib + docetaxel cohorts, respectively. While exposure to study medication was acceptable (mean relative dose
intensity of glesatinib was 90.7% and 89.6% in the erlotinib
and docetaxel groups, respectively) and the adverse effect
profile of both treatment combinations was suggestive of
biological activity, it is likely that lack of genetic selection
impacted efficacy findings. Indeed, selection for MET and
AXL was planned for further cohorts in this study, which
did not proceed due to early termination. These included
planned phase I expansion cohorts at the MTD or MAD in
each study arm, and a phase II randomized portion investigating glesatinib plus erlotinib versus glesatinib plus docetaxel in patients with stage 3b/4 NSCLC and MET-positive
disease and/or AXL overexpression or translocation.
In the dose-escalation portion of this study, the MAD of
glesatinib (micronized V2) was 700 mg twice daily in combination with erlotinib 150 mg once daily, or with docetaxel
75 mg/m2 every 3 weeks. Two of five evaluable patients
experienced DLTs of Grade 3 diarrhea at the glesatinib +
erlotinib MAD, and two of six evaluable patients experienced DLTs of Grade 2 acute pancreatitis (which resulted
in study discontinuation) and Grade 3 elevated AST at the
glesatinib + docetaxel MAD. While the MTD of glesatinib
with either erlotinib or docetaxel was not formally established, the numbers of DLTs observed at the MAD of both
treatment combinations suggests glesatinib (V2 micronized)
700 mg twice daily in combination with erlotinib or docetaxel exceeded the MTD by a small margin.
The MTD of the glesatinib treatment combinations was
not established because the study was terminated early due
to challenges with the consistency of particle size and bioavailability of glesatinib necessitating further refinement
of the tablet formulation. Indeed, the levels of exposure
achieved at the MAD of glesatinib (V2 micronized) 700 mg
twice daily administered with either erlotinib or docetaxel
were considered suboptimal to achieve complete inhibition of MET or AXL, based on preclinical data. Following
preliminary observations of a lack of increased exposure at
glesatinib with the initial unmicronized formulation assessed
at doses > 96 mg/m2, attempts were made to improve drug
absorption during the course of this study. These included
micronization and a micronized formulation of glesatinib
containing sodium lauryl sulphate (V2 tablets) in order to
reduce particle size and increase the rates of dissolution and
solid dispersion [22]. However, PK data comparing the different formulations of glesatinib were variable and inconclusive, likely due in part to small numbers of patients in
each cohort and high interpatient variability. Systemic exposure to glesatinib increased in a less than dose proportional
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manner, with no clinically meaningful differences in exposure or bioavailability between the tested formulations. Suboptimal drug formulation, including poor solubility, stability
and/or biodistribution, is an inherent challenge of developing
novel agents, due in part to limitations in the prediction of
drug bioavailability in humans [23]. This underscores the
need to improve preclinical evaluations, to effectively predict
PK parameters in the clinic, and physiochemical studies,
to inform particle size specification and optimize manufacturing consistency, thereby guiding the refinement of novel
drug formulations. Findings from another phase I study,
investigating other formulations of glesatinib as monotherapy, impacted the present study (results to be reported separately). Rather than glesatinib glycolate as investigated in
this study, this resulted in further assessments of glesatinib,
including MTD, being focused on free-base formulations:
glesatinib FBS capsule (glesatinib free base suspended in
Miglycol®) and glesatinib SDD tablet (spray-dried dispersion tablet comprising amorphous solid dispersion of glesatinib free base in a polymer matrix).

5 Conclusion
The safety profile of glesatinib glycolate formulations in
combination with erlotinib and docetaxel was acceptable
and no PK interactions were identified. Modest signals
of efficacy with these treatment combinations were also
observed in patients with genetically unselected, advanced
solid tumors. Based on other emerging phase I data, further investigation of glesatinib focused on alternate free
base formulations that aimed to improve drug bioavailability
and centered on patients with activating MET alterations
(ClinicalTrials.gov identifier: NCT02544633; data to be
reported separately). While the data from the present study
could guide dose selection for future combination trials of
reformulated glesatinib, clinical development of glesatinib
was ultimately terminated because bioavailability challenges
impacted the ability to achieve exposure levels required for
optimal efficacy.
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